簡要描述:泛素樣蛋白Sumo2抗體注意事項(xiàng);This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
泛素樣蛋白Sumo2抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
泛素樣蛋白Sumo2抗體 | Sumo2 | GOY-01K0675 |
商品屬性:
英文名稱: Sumo2
中文名:泛素樣蛋白Sumo2抗體
別 名;Small
ubiquitin-related modifier 2; SUMO-2; Sumo 2; HSMT3; SMT3 homolog 2; SUMO-3;
Sentrin-2; Ubiquitin-like protein SMT3A; Smt3A; SUMO2_HUMAN.
研究領(lǐng)域;細(xì)胞生物 免疫學(xué) 細(xì)胞凋亡 泛素
抗體來源;Rabbit
克隆類型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, Rat, Pig, Cow, Rabbit, )
產(chǎn)品應(yīng)用;WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;10.9kDa
細(xì)胞定位;細(xì)胞核 細(xì)胞漿
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human Sumo2: 1-80/95
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
The small ubiquitin-related modifier (SUMO)
proteins, which include SUMO-1, SUMO-2 and SUMO-3, belong to the
ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are
synthesized as precursor proteins that undergo processing before conjugation
to target proteins. Also, both utilize the E1, E2, and E3 cascade enzymes for
conjugation. However, SUMO and ubiquitin differ with respect to targeting.
Ubiquitination predominantly targets proteins for degradation, whereas
sumoylation targets proteins to a variety of cellular processing, including
nuclear transport, transcriptional regulation, apoptosis and protein
stability. The unconjugated SUMO-1, SUMO-2 and SUMO-3 proteins localize to
the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1
utilizes Ubc9 for conjugation to several target proteins, which include IkBa,
MDM2, p53, PML and Ran GAP1. SUMO-2 and SUMO-3 contribute to a greater
percentage of protein modification than does SUMO-1, and unlike SUMO-1, they
can form polymeric chains. In addition, SUMO-3 regulates b-Amyloid generation
and may be critical in the onset or progression of Alzheimer’s disease Ubiquitin-like protein that can be covalently
attached to proteins as a monomer or as a lysine-linked polymer. Covalent
attachment via an isopeptide bond to its substrates requires prior activation
by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be
promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4. This
post-translational modification on lysine residues of proteins plays a
crucial role in a number of cellular processes such as nuclear transport, DNA
replication and repair, mitosis and signal transduction. Polymeric SUMO2
chains are also susceptible to polyubiquitination which functions as a signal
for proteasomal degradation of modified proteins. |
多克隆抗體制備:
我公司合成抗原,保證陽性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測結(jié)果是陽性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專業(yè)的建議。在制備過程中,與客戶互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽性血清檢測達(dá)到合同要求的同時(shí),也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無法做到的。我公司已搭建好的抗體測序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶提供各種類型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測試的客戶量身定制的專業(yè)服務(wù),主要面向工業(yè)客戶。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃